Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338479 | 0.80 | MAPT (0.67) | TDP1ALDH1A1MAPTMEN1HSP90AA1 | |
| SCHEMBL1982414 | 0.77 | ALDH1A1 (0.63) | TSHRTDP1ALDH1A1MAPTMEN1 | |
| SCHEMBL11689839 | 0.77 | LOXL2 (0.52) | TSHRCYP2C19CYP1A2LOXL2ALDH1A1 | |
| SCHEMBL16246201 | 0.77 | LOXL2 (0.57) | TSHRCYP2C19CYP1A2LOXL2ALDH1A1 | |
| SCHEMBL4223676 | 0.75 | LOXL2 (0.59) | TSHRCYP2C19CYP1A2LOXL2ALDH1A1 | |
| SCHEMBL523810 | 0.74 | LOXL2 (0.57) | TSHRCYP2C19CYP1A2LOXL2ALDH1A1 | |
| SCHEMBL30486033 | 0.74 | FFAR1 (0.47) | TSHRCYP1A2TDP1MAPTMEN1 | |
| SCHEMBL30643815 | 0.72 | CYP2C19 (0.64) | TSHRCYP2C19CYP1A2LOXL2TDP1 | |
| SCHEMBL76204 | 0.72 | CYP2C19 (0.64) | TSHRCYP2C19CYP1A2LOXL2TDP1 | |
| SCHEMBL4521415 | 0.72 | PYCR1 (0.57) | TSHRCYP2C19CYP1A2LOXL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186752-B2 | Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SCRAS (FR) | 2007-03-06 | — | — | US | disclosed |
| US-20050197329-A1 | Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SCRAS | 2005-09-08 | — | — | US | disclosed |
| EP-0050927-B1 | THE PREPARATION OF BETA-LACTAM ANTIBIOTICS | BEECHAM GROUP PLC (GB) | 1985-03-27 | — | — | EP | disclosed |
| US-4438036-A | β-Lactam antibiotics their preparation and their use | BEECHAM GROUP LIMITED (GB) | 1984-03-20 | — | — | US | disclosed |
| EP-0050927-A1 | The preparation of beta-lactam antibiotics | BEECHAM GROUP PLC (GB) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197329-A1 | Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS1, NOS2, NOS3 | TSHR 2044/4885CYP2C19 315/4885CYP1A2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.